http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102451249-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73adec9b4d9a1c07892f3285884fc63d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 |
| filingDate | 2010-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57c9e4ce932a5d34155df9828349ca78 |
| publicationDate | 2013-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102451249-B |
| titleOfInvention | Drug for treating burn and scald, and application thereof |
| abstract | The present invention provides a drug for treating burn and scald. The drug comprises a drug composition and/or a pharmaceutically-acceptable carrier, and is characterized in that: the drug composition mainly comprises the following raw material drugs, wherein the raw material drugs comprise, by weight, 10-20 parts of common melastoma herb, 15-25 parts of narrowleaf screwtree root, 10-25 parts of mallotus apelta, 10-20 parts of breynia fruticosa, 10-20 parts of parasite scurrula, 10-20 parts of rhapniolepisindica, and a proper amount of antibiotic. The application for the drug comprises that: according to the weight part ratio, the raw material drugs are dried in the sun and grinded, a debridement treatment is performed on a wound, then the wound is cleaned, the blister is pierced from the side surface by using a sterile needle to remove the water, the blister skin removal is not required, the grinded raw material drugs are externally coated on the wound position, and the dressing is not required, such that the disease condition is easily observed, and the pain on the patient during the dressing changing process is reduced. The drug is usually applied twice a day, and the effect can be provided after continuously using the drug for about a week. |
| priorityDate | 2010-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.